Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ibio Inc IBIO

Healthcare Biotechnology
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu... see more

Recent & Breaking News (NYSEAM:IBIO)

iBio to Present at Brazilian Ministry of Health’s Plant-Made Pharmaceutical Meeting

GlobeNewswire December 3, 2018

iBio and CC-Pharming Hold First Design and Strategy Meeting

GlobeNewswire October 2, 2018

iBio, Inc. Announces NYSE American Acceptance of Plan of Compliance

GlobeNewswire August 22, 2018

iBio Establishes Strategic Commercial Relationship with CC-Pharming Ltd. of Beijing, China

GlobeNewswire July 9, 2018

iBio, Inc. Closes $16,000,000 Public Offering

GlobeNewswire June 26, 2018

iBio, Inc. Prices $16,000,000 Public Offering

GlobeNewswire June 22, 2018

iBio, Inc. Announces Completion of 1-For-10 Reverse Stock Split

GlobeNewswire June 8, 2018

iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance Plan

GlobeNewswire June 8, 2018

iBio and ONEWAY Diagnostica Develop New Products for Brazil

GlobeNewswire June 5, 2018

iBio, Inc. Announces Reverse Stock Split

GlobeNewswire May 31, 2018

iBio Appoints James Abbey, Ph.D. as Vice President of Strategic Business Development

GlobeNewswire October 2, 2017

iBio, Inc. Intellectual Property Update

GlobeNewswire September 20, 2017

iBio Makes NYSE MKT Section 610(b) Public Announcement

GlobeNewswire September 19, 2017

iBio and TheoremDx Collaborate to Develop Proteins for Rapid Diagnostics Testing Products

GlobeNewswire September 18, 2017

AzarGen Biotechnologies Granted European Patent for Plant-Made PRODUCTION OF RECOMBINANT HUMAN SURFACTANT PROTEIN-B

PR Newswire July 25, 2017

iBio, Inc. Enters into Common Stock Purchase Agreement for Up to $16.0 Million with Lincoln Park Capital

GlobeNewswire July 24, 2017

US Patent Granted to AzarGen Biotechnologies for Synthetic Promoter Technology

PR Newswire July 12, 2017

iBio, Inc. to Present Plant-Made Pharmaceutical Platform at Plant-Based Vaccines, Antibodies & Biologics Conference

GlobeNewswire June 5, 2017

iBio, Inc. Provides Corporate Update at Annual Shareholders Meeting

Marketwired May 4, 2017

Court Schedules Hearing To Consider Approval Of Settlement Of Derivative Action

Marketwired January 27, 2017